Literature DB >> 25030390

Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose.

Tarun Singhal1, Abass Alavi2, Chun K Kim3.   

Abstract

Several PET radiopharmaceuticals beyond FDG have been used to study the physiology and pathophysiology in neurosciences. This article provides a broad overview of some of the commonly studied radiopharmaceuticals for PET imaging in selected neurologic conditions, particularly attempting to study their clinical relevance. Future studies on the use of advanced PET imaging in delineating neural pathophysiology, drug development, and altering patient management and outcomes across the disciplines of neurosciences are needed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain; Central nervous system; Dementia; Epilepsy; Neuroinflammation; Parkinson disease; Positron; Positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 25030390     DOI: 10.1016/j.cpet.2014.03.009

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  3 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

Review 2.  (18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy.

Authors:  Marina Hodolic; Raffi Topakian; Robert Pichler
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

Review 3.  Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.

Authors:  Ji Hoon Jung; Byeong Cheol Ahn
Journal:  Brain Tumor Res Treat       Date:  2018-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.